- Oops!Something went wrong.Please try again later.
Mr. Mark Haden appointed to VP Business Development and Mr. Gilad Babchuk as Head of Strategy and Communication
TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce senior appointments to its management team in North America.
Mr. Mark Haden, psychedelic medicine expert, has been appointed as the Company’s Vice President Business Development. Mr. Haden was promoted to this position after serving as one of the founding members of Clearmind's scientific advisory.
Mr. Haden has spent his career working to advance the use of psychedelics in medicine. Mark has substantial research experience, including a leadership role in the study of Psilocybin Research Investigating Medical Efficacy, which explores psilocybin as an adjunct in the treatment of substance use disorders, and has spent 10 years as the chairman and executive director of the Multidisciplinary Association for Psychedelic Studies in Canada, an organization he founded. He has also dedicated over 25 years to working directly with patients through the Vancouver Coastal Health Addiction Services. Mr. Haden currently serves as Director of Clinical Research at Psygen Industries, a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications and is an Adjunct Professor at the University of British Columbia School of Population and Public Health.
Additionally, the Company wishes to announce that, Mr. Gilad Babchuk has been appointed as the Company’s Head of Strategy and Communication. Mr. Babchuk is a serial entrepreneur with 28 years of global experience in establishing, developing, and running organizations. He served as a strategic advisor to top-level managers in both the private and public sectors as well as to certain politicians at various governmental levels. He was a founder and co-founder of over 15 social ventures, as well as a 4-time CEO. Gilad is an acclaimed speaker and is currently a consultant for multinational companies, working with senior CEOs, business leaders, and entrepreneurs worldwide.
Dr. Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “As we continue to increase our footprint in North America, I am excited to welcome our newest team members. Since joining our scientific advisory board, Adjunct Prof. Haden's contributions have been plentiful and we believe that as VP of Business Development, his expertise and connections will greatly improve the future progression of the company."
“Mr. Babchuk has decades of experience in taking companies to their next stage with well-established strategies and tactics. I am confident that our new team members will support Clearmind in achieving its goals for the upcoming year and will facilitate efforts in North America,” Zuloff-Shani added.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of four patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND", the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol "CMNDF".
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.